Table of Contents Author Guidelines Submit a Manuscript
Bone Marrow Research
Volume 2011 (2011), Article ID 579268, 3 pages
Research Article

Hyperbaric Oxygen Therapy as a Sole Agent Is Not Immunosuppressant in a Highly Immunogenic Mouse Model

1Division of Haematology/Oncology/BMT, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, Canada M5G 1X8
2Division of Immunology and Allergy, The Hospital for Sick Children, University of Toronto, ON, Canada M5G 1X8
3Hyperbaric Medicine Unit, University Health Network, Toronto General Hospital, Faculty of Medicine, University of Toronto, ON, Canada M5G 2C4
4Animal Facilities, Faculty of Dentistry, University of Toronto, Toronto, ON, Canada M5G 1G6
5Oral and Maxillofacial Surgery, University of Toronto, Toronto, ON, Canada M5G 1G6
6Tissue Engineering, Regea Institute for Regenerative Medicine, University of Tampere, 33520 Tampere, Finland

Received 7 May 2010; Accepted 18 June 2010

Academic Editor: Axel R. Zander

Copyright © 2011 Adam Gassas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Hyperbaric oxygen (HBO) therapy, which is used for many conditions, may also have immunosuppressive effects and could be used for prevention or treatment of graft-versus-host disease (GvHD). If HBO is immunosuppressant, then we hypothesize that HBO therapy will delay the T-cell mediated skin graft rejection. Methods. C57/BL6 black-coated (H2B) mice received skin graft from CBA (H2D) white-coated mice. Mice were treated with either 19 session of 240 kpa oxygen or 29 session of 300 kpa oxygen, for 90 minutes. Mice were housed either 4 per cage or separately, to prevent friction and mechanical factors that may affect graft survival. Skin grafts were assessed daily. Results. There was no difference in length of graft survival between mice that received either regimens of HBO therapy and mice that did not receive HBO therapy. Conclusions. HBO therapy, as a sole agent, did not delay skin graft rejection in a highly immunogenic mouse model.